Tempus ECG-AF vs Mindbowser AI Cardiovascular Risk Prediction
AI Verdict
Choose Tempus ECG-AF if…
Choose Tempus ECG-AF if your primary objective is to specifically identify patients aged 65 or older, without pre-existing AF, who are at an increased risk of developing new-onset atrial fibrillation within the next 12 months, utilizing their 12-lead ECG recordings. This tool is ideal for proactive screening and earlier intervention in a defined elderly population to prevent future AF events.
View Tempus ECG-AF →Choose Mindbowser AI Cardiovascular Risk Prediction if…
Choose Mindbowser AI Cardiovascular Risk Prediction if you need a comprehensive, cloud-based solution for general cardiovascular risk assessment across a wider patient population, with strong emphasis on seamless integration with major EHR systems (Epic, Cerner, Athenahealth). This tool is best suited for healthcare providers and hospitals looking for robust clinical decision support, data analytics, and AI-powered automation to enhance overall cardiovascular care pathways.
View Mindbowser AI Cardiovascular Risk Prediction →Reviewed by Pouyan Golshani, MD — Interventional Radiologist
Quick Comparison
| Feature | Tempus ECG-AF | Mindbowser AI Cardiovascular Risk Prediction |
|---|---|---|
| Pricing | Contact vendor | Contact for pricing |
| Deployment | Software solution, integrated into healthcare facility systems with advanced cardiology algorithms. | Cloud-based |
| BAA Available | Yes AI-estimated | Yes AI-estimated |
| FDA Status | Yes AI-estimated | Unknown |
| HIPAA | Yes AI-estimated | Yes AI-estimated |
Head-to-Head
AI-generated assessment across six dimensions based on each tool's documented features and compliance posture. Grounded in public data — not a substitute for hands-on evaluation.
Usability
Mindbowser AI Cardiovascular Risk PredictionMindbowser's AI Cardiovascular Risk Prediction is described as cloud-based with seamless EHR integration and offers real-time dashboards and automated patient engagement features, suggesting a direct and interactive user experience for clinicians. In contrast, Tempus ECG-AF operates as a backend algorithm without a dedicated user interface, integrating its results into existing medical systems via APIs or file exchanges.
Clinical Value
Tempus ECG-AFTempus ECG-AF holds FDA clearance for its specific clinical indication: identifying patients aged 65 or older at increased risk of developing atrial fibrillation within 12 months, based on 12-lead ECGs. This is supported by a large training dataset of over 1.5 million ECGs and a 95% negative predictive value. While Mindbowser claims improvements in early detection and reduced hospitalizations, it lacks comparable specific regulatory clearances or detailed clinical validation studies in the provided information.
Pricing & Value
Tempus ECG-AFTempus ECG-AF clearly outlines its value proposition with established CMS reimbursement available (CPT 0764T and CPT 0765T to APC 5734, Medicare rate of $128.90, effective January 1, 2025). Mindbowser's tool only states 'contact for pricing,' offering no transparent details on cost or potential reimbursement, making its economic value less clear.
Enterprise Readiness
Mindbowser AI Cardiovascular Risk PredictionBoth tools demonstrate strong enterprise readiness, with HIPAA compliance and integration capabilities. However, Mindbowser's AI Cardiovascular Risk Prediction explicitly highlights SOC 2 compliance and a broader range of specific EHR integrations (Epic, Cerner, Athenahealth, FHIR) with HL7 & FHIR interoperability, indicating a more comprehensive approach to enterprise-level deployment and data exchange.
Innovation
Tempus ECG-AFTempus ECG-AF stands out for its innovative application of AI, being the first FDA-cleared algorithm in its category to predict the risk of new-onset atrial fibrillation within 12 months from a standard 12-lead ECG. This represents a specific, validated predictive capability for a serious condition. Mindbowser's offering, while valuable, describes more general AI applications in cardiovascular risk prediction and clinical decision support.
Support & Docs
Tempus ECG-AFTempus ECG-AF provides explicit contact information for technical support, including a dedicated email address ([email protected]) and phone number (800.739.4137). Mindbowser's information is more general, directing users to a 'Contact Us' section without specifying dedicated support channels or readily available documentation.
Feature-by-Feature
Detail beyond the Quick Comparison summary. For pricing, deployment, BAA, FDA, and HIPAA see the Overview tab.
| Feature | Tempus ECG-AF | Mindbowser AI Cardiovascular Risk Prediction |
|---|---|---|
| Tool Name | Tempus ECG-AF | Mindbowser AI Cardiovascular Risk Prediction |
| Company | Tempus AI, Inc. | Mindbowser |
| Description | FDA-cleared AI-based algorithm that analyzes 12-lead ECG recordings to identify patients aged 65 or older at increased risk of developing atrial fibrillation/flutter (AF) within the next 12 months, supporting earlier identification and follow-up. | Part of their comprehensive suite of healthcare AI solutions, designed for providers and hospitals to assess cardiovascular risks. It emphasizes compliance with HIPAA and SOC 2 and integrates with leading EHR systems. |
| Key Features | AI-based algorithm for 12-lead ECG analysis, Detects signs associated with new onset Atrial Fibrillation (AF) within 12 months, Intended for patients 65 years or older without pre-existing AF, pacemakers, ICDs, or recent cardiac surgery, Results interpreted in conjunction with other diagnostic information and clinical history, Compatible with FDA authorized resting 12-lead ECGs from GE Medical Systems and Philips Medical Systems, Trained on over 1.5 million ECGs from over 500,000 patients | AI Cardiovascular Risk Prediction, AI-powered automation, HIPAA and SOC 2 compliance, EHR integration (Epic, Cerner, Athenahealth, FHIR), Clinical Decision Support System, Data & Analytics, HL7 & FHIR interoperability, Secure, compliant healthcare data access |
| Target Patient Population | Patients aged 65 or older at increased risk of developing atrial fibrillation/flutter (AF) within the next 12 months, without pre-existing AF, pacemakers, ICDs, or recent cardiac surgery. | Not specified |
| Reimbursement | CMS reimbursement available (CPT 0764T and CPT 0765T to APC 5734, Medicare rate of $128.90, effective January 1, 2025). | Not specified |
Videos
Demos, reviews, and walkthroughs featuring Tempus ECG-AF and Mindbowser AI Cardiovascular Risk Prediction.